ACAD vs BIO
ACADIA Pharmaceuticals Inc. vs Bio-Rad Laboratories — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
62
Buy
VS
BIO
Bio-Rad Laboratories
59
Buy
| Metric | ACAD | BIO |
|---|
| AI Score |
62
|
59
|
| Price |
$29.50
|
$379.85
|
| P/E Ratio |
13.11×
|
45.62×
|
| ROE |
31.9%
|
10.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
51.9%
|
| Debt / Equity |
0.06×
|
0.17×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
59.6
|
82.3
|
| Beta |
0.845
|
1.047
|
| Expected Upside |
—
|
+0.6%
|
AI Committee View
Current Innellis committee reasoning for ACAD versus BIO.
ACAD leads by 3 points.
ACAD scores 62/100 (Buy) versus BIO at 59/100 (Buy).
ACAD Committee View
60% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — quarter-over-quarter growth rate is accelerating, not just positive. Risk Analyst remains cautious — bollinger bandwidth of 22.8% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Bollinger bandwidth of 22.8% signals elevated volatility — Risk
BIO Committee View
67% agreement
6 analysts
Positive signals support the current rating — news sentiment is positive (+0.57 across 7 articles, 14d). The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 43.5 is expensive by classic value standards — Value
- ROE of only 3.1% -- cheap may mean cheap for a reason — Value
- EPS declining -29.6% YoY despite any revenue growth — Growth